Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. — ME/CFS Atlas
E3 PreliminaryWeak / uncertainPEM not requiredRCTPeer-reviewedReviewed
Standard · 3 min
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Westin, J, Rödjer, S, Turesson, I et al. · British journal of haematology · 1995 · DOI
Quick Summary
This study tested whether a drug called interferon alfa-2b could help multiple myeloma patients (a type of blood cancer) stay in remission longer after their initial treatment. Patients who received interferon stayed in remission for about 14 months compared to 6 months for those who didn't, but both groups lived about the same length of time overall.
Why It Matters
This study is relevant to ME/CFS research because it documents 'chronic fatigue syndrome' as a medication side effect in 18% of treated patients, providing evidence that certain pharmacological interventions can induce fatigue-like toxicity. Understanding drug-induced fatigue mechanisms may inform understanding of post-treatment or exertional malaise in ME/CFS populations and highlight the need for improved toxicity monitoring in clinical trials.
Observed Findings
Interferon alfa-2b prolonged median plateau phase to 13.9 months versus 5.7 months in control group (P<0.0001).
Chronic fatigue syndrome occurred in 18% of interferon-treated patients at WHO grade 3 toxicity level.
Moderate granulocytopenia was the most frequent side effect (22% WHO grade 3) in treated group.
Median overall survival from randomization was 36 months (interferon) versus 35 months (control)—not statistically different.
59% of enrolled patients achieved response to induction therapy; 49% reached plateau phase.
Inferred Conclusions
Interferon maintenance therapy reliably prolongs disease plateau phase in responding multiple myeloma patients with acceptable tolerability.
The lack of overall survival benefit suggests plateau prolongation may not translate to clinical benefit despite response rate improvements.
Further studies are needed to establish whether interferon maintenance has clinical utility given the disconnect between disease progression markers and patient survival.
Remaining Questions
What mechanisms underlie the fatigue syndrome induced by interferon, and how do they compare to ME/CFS pathophysiology?
Why does prolongation of plateau phase not translate to improved overall survival, and what factors determine survival in this population?
What This Study Does Not Prove
This study does not establish that interferon-induced fatigue shares pathophysiology with ME/CFS, nor does it explain mechanisms of fatigue development. The fatigue described is a documented adverse effect in cancer treatment, not a study of ME/CFS etiology or pathogenesis. Survival benefit absence does not prove prolonged plateau phase lacks clinical value in all patient contexts.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.